potential indications for glp-1 receptor agonists keep expanding Nutritional priorities to support therapy obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society GLP-1 Receptor Agonists | New

For patients with BMI 35 kg/m (regardless of comorbidities) or BMI 30-34.9 kg/m with metabolic disease, bariatric surgery consultation may be appropriate, according to 2022 American Society for Metabolic and Bariatric Surgery guidelines

It reflects the reality that individual biology creates enormous variation in drug response

We thank Eduard Kober, Hlne Savoye (both employed by Sanofi), and Mlanie Bovo (employed by Business France) for their support during the conduct and analysis of this study

GLP-1s for Chronic Kidney Disease GLP-1s for Advanced Liver Disease In August 2025, the FDA approved Wegovy (semaglutide) to treat adults with a type of liver disease called metabolic-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), when used alongside diet and exercise